Refractory Angina – Pipeline Review, H1 2012

Date: May 28, 2012
Pages: 22
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RE498C9229AEN
Leaflet:

Download PDF Leaflet

Refractory Angina – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Refractory Angina - Pipeline Review, H1 2012', provides an overview of the Refractory Angina therapeutic pipeline. This report provides information on the therapeutic development for Refractory Angina, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Angina. 'Refractory Angina - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Refractory Angina.
  • A review of the Refractory Angina products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Refractory Angina pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Refractory Angina.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Refractory Angina pipeline depth and focus of Refractory Angina therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords

Refractory Angina Therapeutic Products under Development, Key Players in Refractory Angina Therapeutics, Refractory Angina Pipeline Overview, Refractory Angina Pipeline, Refractory Angina Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Refractory Angina Overview
Therapeutics Development
An Overview of Pipeline Products for Refractory Angina
Refractory Angina Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Refractory Angina Therapeutics – Products under Development by Companies
Companies Involved in Refractory Angina Therapeutics Development
Ark Therapeutics Group plc
Refractory Angina – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
EG011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refractory Angina Therapeutics - Dormant Products
Refractory Angina – Product Development Milestones
Featured News & Press Releases
Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Refractory Angina, H1 2012
Products under Development for Refractory Angina – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Ark Therapeutics Group plc, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Refractory Angina Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Refractory Angina, H1 2012
Products under Development for Refractory Angina – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Refractory Angina - Pipeline Review, Q2 2011 US$ 450.00 May, 2011 · 24 pages
Angina - Pipeline Review, Q1 2011 US$ 450.00 Jan, 2011 · 26 pages
Spirogen Ltd. - Product Pipeline Review - 2013 US$ 1,350.00 Dec, 2013 · 34 pages
Agennix AG – Product Pipeline Review – Q4 2010 US$ 450.00 Dec, 2010 · 33 pages

Ask Your Question

Refractory Angina – Pipeline Review, H1 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: